arrow
N

Narendranath Epperla

Huntsman Cancer Institute
H指数:31
被引数:3,498

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models

鉴定套细胞淋巴瘤患者和小鼠模型中的血管生成受体表达

2026-07-240
OA
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

滤泡性淋巴瘤中,嵌合抗原受体T细胞疗法后双特异性抗体疗法的真实世界结局

2026-06-180
OAAI
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers

纳武利尤单抗联合AVD方案作为经典霍奇金淋巴瘤患者的一线治疗方案:一项来自20家美国中心的真实世界分析

2026-03-310
OAAI
Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

大b细胞淋巴瘤继发性中枢神经系统受累的治疗相关结果和复发模式

Blood
IF23.1
2026-01-070
PRE
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium

CAR-T作为二线、三线、四线或更后期治疗在侵袭性B细胞淋巴瘤中的疗效:ABC联盟的真实世界证据

2025-11-100
OAAI
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium

大B细胞淋巴瘤在CAR T细胞治疗失败后使用双特异性抗体的疗效——ABC Consortium研究的结果

2025-10-240
OAAI
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis

CD19靶向CAR T疗法治疗转化型滤泡性淋巴瘤:一项CIBMTR分析

2025-08-050
PRE
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

CAR T细胞疗法中结外受累对复发或难治性大B细胞淋巴瘤患者预后的影响——一项多中心队列研究的结果

2025-06-210
OAAI
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA